{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:20:44Z","timestamp":1783153244116,"version":"3.54.6"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA012197"],"award-info":[{"award-number":["P30CA012197"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ACS IRG-22-157-01-IRG"],"award-info":[{"award-number":["ACS IRG-22-157-01-IRG"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA172513"],"award-info":[{"award-number":["CA172513"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["K12TR004931"],"award-info":[{"award-number":["K12TR004931"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007154","name":"Wake Forest University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002576","name":"American Cyronics Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002576","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["R01 CA215651"],"award-info":[{"award-number":["R01 CA215651"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118944","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:29:01Z","timestamp":1778858941000},"page":"118944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K\/BRD4 inhibitors"],"prefix":"10.1016","volume":"315","author":[{"given":"Krishnaiah","family":"Maddeboina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharath","family":"Yada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody C.","family":"McHale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhananjaya","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashpal S.","family":"Chhonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J.","family":"Murry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Soto-Pantoja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Durden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2026.118944_bib1","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118944_bib2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/hematology.2025000722","article-title":"Emerging immunotherapy advances for Non-Hodgkin lymphomas: engaging T cells in the fight","volume":"2025","author":"Rojek","year":"2025","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118944_bib3","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1021\/cr400265z","article-title":"Chromone: a valid scaffold in medicinal chemistry","volume":"114","author":"Gaspar","year":"2014","journal-title":"Chem Rev"},{"key":"10.1016\/j.ejmech.2026.118944_bib4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejmech.2014.03.047","article-title":"Chromones as a privileged scaffold in drug discovery: a review","author":"Keri Rs","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118944_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3892\/ijmm.2017.3036","article-title":"The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)","volume":"40","author":"Ardito","year":"2017","journal-title":"Int. J. Mol. Med."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118944_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/1359-6446(96)10030-1","article-title":"Protein kinase inhibitors for the treatment of cancer","volume":"1","author":"Patrick Dr","year":"1996","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118944_bib7","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1042\/BST20130097","article-title":"Structural characterization of the cyclin-dependent protein kinase family","volume":"41","author":"Endicott","year":"2013","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejmech.2026.118944_bib8","doi-asserted-by":"crossref","first-page":"9185","DOI":"10.1073\/pnas.91.19.9185","article-title":"The phosphatidylinositol 3-kinase alpha is required for DNA synthesis induced by some, but not all, growth factors","author":"Roche S","year":"1994","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118944_bib9","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1021\/cb500072z","article-title":"Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors","volume":"9","author":"Ember","year":"2014","journal-title":"ACS Chem. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118944_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2217\/epi.14.91","article-title":"Targeting BET bromodomains for cancer treatment","volume":"7","author":"Jung","year":"2015","journal-title":"Epigenomics"},{"issue":"22","key":"10.1016\/j.ejmech.2026.118944_bib11","doi-asserted-by":"crossref","first-page":"E5086","DOI":"10.1073\/pnas.1712363115","article-title":"Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma","volume":"115","author":"Xu","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118944_bib12","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ccell.2018.11.005","article-title":"Resistance to epigenetic-targeted therapy engenders tumor cell vulnerabilities associated with enhancer remodeling","volume":"34","author":"Iniguez","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118944_bib13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/jcb.26264","article-title":"BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC","volume":"119","author":"Ba","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118944_bib14","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1016\/S0021-9258(17)37680-9","article-title":"A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)","volume":"269","author":"Vlahos","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2026.118944_bib15","first-page":"4412","article-title":"Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant","volume":"63","author":"Shivakrupa","year":"2003","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118944_bib16","first-page":"880","article-title":"In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002)","volume":"6","author":"Hu","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118944_bib17","first-page":"3585","article-title":"PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment","volume":"63","author":"Su","year":"2003","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118944_bib18","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/j.1349-7006.2008.00891.x","article-title":"Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy","volume":"99","author":"Kong","year":"2008","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118944_bib19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/0008-5472.CAN-07-0669","article-title":"A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity","volume":"68","author":"Garlich","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118944_bib20","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5c01688","article-title":"Discovery of a \"First-in-Class\" selective multikinase (CDK4\/6\/9-AURKA\/B) inhibitor, LCI133, for neuroblastoma","author":"Maddeboina","year":"2025","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118944_bib21","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1021\/jm301522m","article-title":"Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors","volume":"56","author":"Morales","year":"2013","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118944_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5643","article-title":"LC-MS\/MS method for the quantitation of a dual PI3K\/BRD4 inhibitor SF2523 in mouse plasma: application to plasma protein binding and metabolism studies","volume":"37","author":"Bala","year":"2023","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejmech.2026.118944_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2022.12.055","article-title":"Targeting BRD4 and PI3K signaling pathways for the treatment of medulloblastoma","volume":"354","author":"Sethi","year":"2023","journal-title":"J Control Release"},{"issue":"36","key":"10.1016\/j.ejmech.2026.118944_bib24","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2306414120","article-title":"Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma","volume":"120","author":"Oh","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"21","key":"10.1016\/j.ejmech.2026.118944_bib25","doi-asserted-by":"crossref","first-page":"23078","DOI":"10.1021\/acs.jmedchem.5c01920","article-title":"Discovery of novel PI3K\/BRD4 dual inhibitors for esophageal cancer: rational design, optimization, and senescence-inducing mechanisms","volume":"68","author":"Peng","year":"2025","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118944_bib26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1158\/1535-7163.MCT-19-0947","article-title":"Macrophage Syk-PI3Kgamma inhibits antitumor immunity: SRX3207, a novel dual Syk-PI3K inhibitory chemotype relieves tumor immunosuppression","volume":"19","author":"Joshi","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118944_bib27","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1016\/j.bmcl.2004.03.043","article-title":"PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues","volume":"14","author":"Abbott","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118944_bib28","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1021\/acs.jmedchem.3c01837","article-title":"Structure-guided design and synthesis of Pyridinone-Based selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitors","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118944_bib29","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1021\/acs.jmedchem.4c00078","article-title":"Discovery of pyridopyrimidinones that selectively inhibit the H1047R PI3Kalpha mutant protein","volume":"67","author":"Ketcham","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118944_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095893","article-title":"Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo","volume":"9","author":"Joshi","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118944_bib31","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1541-7786.MCR-13-0682","article-title":"A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1alpha and HIF2alpha stability and tumor growth, angiogenesis, and metastasis","volume":"12","author":"Joshi","year":"2014","journal-title":"Mol. Cancer Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118944_bib32","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/1535-7163.MCT-18-1206","article-title":"SF2523: dual PI3K\/BRD4 inhibitor blocks tumor immunosuppression and promotes adaptive immune responses in cancer","volume":"18","author":"Joshi","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"10.1016\/j.ejmech.2026.118944_bib33","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1182\/bloodadvances.2020003871","article-title":"Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis","volume":"5","author":"Le","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118944_bib34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10238-023-01291-y","article-title":"Macrophages and angiogenesis in human lymphomas","volume":"24","author":"Ribatti","year":"2024","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118944_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12814","article-title":"The prognostic value of tumour-associated macrophages in non-hodgkin's lymphoma: a systematic review and meta-analysis","volume":"91","author":"Xu","year":"2020","journal-title":"Scand. J. Immunol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118944_bib36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3324\/haematol.2015.124008","article-title":"Tumor-associated macrophages in diffuse large B-cell lymphoma","volume":"100","author":"Kridel","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118944_bib37","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/ni.1920","article-title":"The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection","volume":"11","author":"Satoh","year":"2010","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118944_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110719","article-title":"Type I interferon antagonism of the JMJD3-IRF4 pathway modulates macrophage activation and polarization","volume":"39","author":"Ming-Chin Lee","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118944_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978262","article-title":"Jmjd3\/IRF4 axis aggravates myeloid fibroblast activation and m2 macrophage to myofibroblast transition in renal fibrosis","volume":"13","author":"Liang","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118944_bib40","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/intimm\/dxad028","article-title":"NOTCH4 potentiates the IL-13 induced genetic program in M2 alternative macrophages through the AP1 and IRF4-JMJD3 axis","volume":"35","author":"Lopez-Lopez","year":"2023","journal-title":"Int. Immunol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118944_bib41","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cmet.2012.04.023","article-title":"The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism","volume":"15","author":"Haschemi","year":"2012","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118944_bib42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.immuni.2015.02.005","article-title":"Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization","volume":"42","author":"Jha","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2026.118944_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.918747","article-title":"Perspective on direction of control: cellular metabolism and macrophage polarization","volume":"13","author":"Thibaut","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118944_bib44","article-title":"Pseudomonas aeruginosa-derived extracellular vesicles enhance macrophage aerobic glycolysis that fuels inflammation","volume":"16","author":"Li","year":"2025","journal-title":"Front. Microbiol."},{"issue":"5425","key":"10.1016\/j.ejmech.2026.118944_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.285.5425.221","article-title":"The immunological synapse: a molecular machine controlling T cell activation","volume":"285","author":"Grakoui","year":"1999","journal-title":"Science"},{"issue":"16_Supplement","key":"10.1016\/j.ejmech.2026.118944_bib46","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1158\/1538-7445.AM2020-3414","article-title":"Abstract 3414: Brd4 inhibition enhances checkpoint therapy by inducing MDSC apoptosis","volume":"80","author":"Carson","year":"2020","journal-title":"Cancer Res."},{"issue":"6_suppl","key":"10.1016\/j.ejmech.2026.118944_bib47","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.2020.38.6_suppl.559","article-title":"Association of myeloid suppressor cells with resistance to checkpoint blockade immunotherapy in urothelial carcinoma","volume":"38","author":"Debasish Sundi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118944_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.728082","article-title":"Brd4 regulates the homeostasis of CD8(+) T-Lymphocytes and their proliferation in response to antigen stimulation","volume":"12","author":"Peng","year":"2021","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118944_bib49","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","article-title":"BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression","volume":"16","author":"Zhu","year":"2016","journal-title":"Cell Rep."},{"issue":"24","key":"10.1016\/j.ejmech.2026.118944_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25245898","article-title":"Assessment of tissue distribution and metabolism of MP1, a novel pyrrolomycin, in mice using a validated LC-MS\/MS method","volume":"25","author":"Aldhafiri","year":"2020","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118944_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4859","article-title":"A rapid and sensitive bioanalytical LC-MS\/MS method for the quantitation of a novel CDK5 inhibitor 20-223 (CP668863) in plasma: application to in vitro metabolism and plasma protein-binding studies","volume":"34","author":"Bala","year":"2020","journal-title":"Biomed. Chromatogr."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118944_bib52","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:09:21Z","timestamp":1783152561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426003892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":52,"alternative-id":["S0223523426003892"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118944","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K\/BRD4 inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118944"}}